AU776162B2 - Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's) - Google Patents

Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's) Download PDF

Info

Publication number
AU776162B2
AU776162B2 AU46712/00A AU4671200A AU776162B2 AU 776162 B2 AU776162 B2 AU 776162B2 AU 46712/00 A AU46712/00 A AU 46712/00A AU 4671200 A AU4671200 A AU 4671200A AU 776162 B2 AU776162 B2 AU 776162B2
Authority
AU
Australia
Prior art keywords
age
formation
compound
pioglitazone
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU46712/00A
Other languages
English (en)
Other versions
AU4671200A (en
Inventor
Jerry L Nadler
Samuel Rahbar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of AU4671200A publication Critical patent/AU4671200A/en
Application granted granted Critical
Publication of AU776162B2 publication Critical patent/AU776162B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU46712/00A 1999-04-29 2000-04-28 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's) Ceased AU776162B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13167599P 1999-04-29 1999-04-29
US60/131675 1999-04-29
PCT/US2000/011355 WO2000066102A2 (en) 1999-04-29 2000-04-28 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)

Publications (2)

Publication Number Publication Date
AU4671200A AU4671200A (en) 2000-11-17
AU776162B2 true AU776162B2 (en) 2004-08-26

Family

ID=22450526

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46712/00A Ceased AU776162B2 (en) 1999-04-29 2000-04-28 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's)

Country Status (6)

Country Link
US (2) US6693106B2 (enExample)
EP (1) EP1210087A2 (enExample)
JP (1) JP2002543118A (enExample)
AU (1) AU776162B2 (enExample)
CA (1) CA2371391A1 (enExample)
WO (1) WO2000066102A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030133B2 (en) 1999-04-05 2006-04-18 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGEs)
US6589944B1 (en) * 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
CN101613321A (zh) * 2002-03-05 2009-12-30 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
GB0312122D0 (en) * 2003-05-27 2003-07-02 Pharmagene Lab Ltd Therapeutic method
JP4976851B2 (ja) 2003-10-27 2012-07-18 シティ・オブ・ホープ 脂質レベルを哺乳動物において低下させる方法
WO2005110468A2 (en) * 2004-05-10 2005-11-24 The Burnham Institute Treatment of insulin resistance/metabolic syndrome to alleviate the risks of dementia
FR2883873B1 (fr) 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
MX2008006204A (es) 2005-11-11 2008-10-17 Aurogen Inc Metodo para tratar por medio de la administracion de insulina la enfermedad o el trastorno del sistema nervioso central asociado con el encogimiento de tejido o atrofia.
NZ571872A (en) * 2006-03-16 2011-05-27 Metabolic Solutions Dev Co Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
DE102007041232A1 (de) 2007-08-30 2009-03-05 Henkel Ag & Co. Kgaa Verwendung von Sulfonylharnstoffen zur Spaltung von AGEs
WO2009030257A1 (en) * 2007-09-05 2009-03-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
JP5371988B2 (ja) * 2007-09-14 2013-12-18 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 高血圧を処置するためのチアゾリジンジオン類似体
DE102007054653A1 (de) 2007-11-14 2009-05-20 Henkel Ag & Co. Kgaa Verwendung von Thioharnstoff-Derivaten zur Spaltung von AGEs
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
HRP20140709T1 (hr) 2008-08-12 2014-09-26 Zinfandel Pharmaceuticals, Inc. Postupak identifikacije faktora rizika za alzheimerovu bolest
GB2465796A (en) * 2008-12-01 2010-06-02 Bee Kang Tan Metformin for the therapeutic use of conditions with raised serum amyloid A levels
WO2010107702A1 (en) * 2009-03-16 2010-09-23 Ipintl, Llc Treating alzheimer's disease and osteoporosis and reducing aging
US8580833B2 (en) 2009-09-30 2013-11-12 Transtech Pharma, Inc. Substituted imidazole derivatives and methods of use thereof
RU2564661C2 (ru) 2009-12-15 2015-10-10 МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи Соли тиазолидиндиона со сниженным сродством к ppar для лечения нарушений обмена веществ
NL1037643C2 (en) * 2010-01-22 2011-07-25 Karel Paul Bouter Nutritional product comprising a biguanide.
KR102171747B1 (ko) 2011-01-10 2020-11-04 진판델 파마슈티컬스 인코포레이티드 알츠하이머 병 치료를 위한 방법 및 약품
US9808434B2 (en) 2011-01-27 2017-11-07 City Of Hope Compound for treating cancer and diabetes
WO2012103523A2 (en) 2011-01-27 2012-08-02 Samuel Rahbar Novel modulators of development of adipocyte and cancer cells
US20150038589A1 (en) * 2011-07-22 2015-02-05 Karel Paul Bouter Nutritional Product Comprising a Biguanide
KR101432246B1 (ko) * 2011-09-20 2014-08-21 가톨릭대학교 산학협력단 메포민을 포함하는 자가면역질환 예방 및 치료용 조성물
ES2589169B1 (es) * 2015-05-06 2017-08-29 Instituto De Investigacion Sanitaria - Fundación Jiménez Díaz Uso de la pentoxifilina y de una composición farmacéutica para elaborar un medicamento para prevenir el envejecimiento prematuro en humanos
WO2019104065A1 (en) * 2017-11-22 2019-05-31 Turrinii Pharmaceutical, Llc Anti-aging methods and compositions
CN114831930B (zh) * 2022-03-28 2023-09-05 厦门大学 一种胶原蛋白组装眼药、制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100919A (en) * 1984-03-19 1992-03-31 The Rockefeller University Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
JPH062675B2 (ja) * 1985-04-05 1994-01-12 ヘキストジヤパン株式会社 記憶障害治療剤
JPH0798794B2 (ja) * 1987-04-01 1995-10-25 大鵬薬品工業株式会社 タウリン型化合物
US5268500A (en) 1987-06-15 1993-12-07 Montefiore Medical Center Compound, composition and method for the reduction of lipids the modification of the affinity of hemoblogin for oxygen and the prevention of platelet aggregation
US4921997A (en) 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
US5093367A (en) 1988-06-15 1992-03-03 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
JP3117823B2 (ja) * 1992-11-17 2000-12-18 鐘紡株式会社 コラーゲン代謝賦活剤
JPH0741423A (ja) * 1993-02-24 1995-02-10 Sankyo Co Ltd 動脈硬化症治療剤
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JPH1029942A (ja) * 1996-04-02 1998-02-03 Yoichi Ichikawa 慢性関節リウマチ治療剤
JPH10212247A (ja) * 1996-05-31 1998-08-11 Sankyo Co Ltd 自己免疫疾患治療剤
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6498193B2 (en) * 1999-12-22 2002-12-24 Trustees Of Dartmouth College Treatment for complications of type 2 diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FERRARI ET AL, PHARMATHERAPEUTICA, VOL. 5(1), 1987, P 26-39 *

Also Published As

Publication number Publication date
EP1210087A2 (en) 2002-06-05
WO2000066102A2 (en) 2000-11-09
JP2002543118A (ja) 2002-12-17
CA2371391A1 (en) 2000-11-09
WO2000066102A3 (en) 2002-03-28
AU4671200A (en) 2000-11-17
US6693106B2 (en) 2004-02-17
US20020123501A1 (en) 2002-09-05
US20020128278A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
AU776162B2 (en) Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's)
EP1165064B1 (en) Novel inhibitors of formation of advanced glycation endproducts (age's)
AU2002252184B2 (en) Novel inhibitors of formation of advanced glycation endproducts (AGEs)
Rahbar et al. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation
Bolton et al. Pimagedine: a novel therapy for diabetic nephropathy
AU2002252184A1 (en) Novel inhibitors of formation of advanced glycation endproducts (AGEs)
EP1372627B1 (en) Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
AU2001255195B2 (en) Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
Roorda Therapeutic interventions against accumulation of advanced glycation end products (AGEs)
AU2004211899B2 (en) Novel inhibitors of formation of advanced glycation endproducts (AGEs)
Rajasekar et al. L-Carnitine inhibits protein glycation in vitro and in vivo: evidence for a role in diabetic management